Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
40,833,657
-
Share change
-
-2,480,284
-
Total reported value
-
$249,084,093
-
Put/Call ratio
-
50%
-
Price per share
-
$6.10
-
Number of holders
-
79
-
Value change
-
-$18,259,465
-
Number of buys
-
31
-
Number of sells
-
36
Institutional Holders of KINNATE BIOPHARMA INC - COM (KNTE) as of Q4 2022
As of 31 Dec 2022,
KINNATE BIOPHARMA INC - COM (KNTE) was held by
79 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,833,657 shares.
The largest 10 holders included
Foresite Capital Management IV, LLC, RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, BlackRock Inc., Nextech Invest Ltd., Vida Ventures Advisors, LLC, FMR LLC, Lynx1 Capital Management LP, VIKING GLOBAL INVESTORS LP, and Avidity Partners Management LP.
This page lists
79
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.